GemVax
Financials
Valuation Metrics
GemVax's Market Cap is ₩3943B. At end of 2025 it was ₩1.3T. Ranked #522 of 2,405 in KR market (top 22%), #199 of 1,627 on KOSDAQ (top 12%), #71 of 212 in Semiconductors & Semiconductor Equipment (top 33%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 394.32B KRW | KR#522/2,405 Sec#71/212 |
| Revenue | 85.10B KRW | KR#1,510/2,405 Sec#130/212 |
| Net Income | -12.23B KRW | KR—/2,405 Sec—/212 |
| Total Assets | 163.11B KRW | KR#1,446/2,405 Sec#127/212 |
| Net Assets | 73.92B KRW | KR#1,637/2,405 Sec#142/212 |
| Employees | 199 | KR#1,110/2,405 Sec#101/212 |
| Value | ||
| P/B | 5.33x | KR#2,269/2,405 Sec#185/212 |
| P/S | 4.63x | KR#2,133/2,405 Sec#169/212 |
| EV/EBITDA | 53.20x | KR#1,369/2,405 Sec#109/212 |
| FCF Yield | 0.03% | KR#1,218/2,405 Sec#102/212 |
| Profitability | ||
| ROE | -16.54% | KR#2,044/2,405 Sec#180/212 |
| ROA | -7.50% | KR#2,031/2,405 Sec#176/212 |
| Op. Margin | 9.97% | KR#522/2,405 Sec#68/212 |
| Revenue Growth | 24.42% | KR#460/2,405 Sec#77/212 |
| Financial Health | ||
| Debt Ratio | 120.66% | KR#1,710/2,405 Sec#164/212 |
| Total Debt | 75.66B KRW | KR#831/2,405 Sec#55/212 |
| FCF | 111.3M KRW | KR#1,214/2,405 Sec#101/212 |
| Cash | 18.64B KRW | KR#1,284/2,405 Sec#127/212 |
| Current Ratio | 1.08x | KR#1,618/2,405 Sec#152/212 |
| Net Debt/EBITDA | 6.72x | KR#1,110/2,405 Sec#106/212 |
| Performance | ||
| 1Y Return | -82.03% | KR#2,353/2,405 Sec#209/212 |
| 1M Return | -22.24% | KR#1,985/2,405 Sec#124/212 |
| From 52W High | -84.21% | KR#2,344/2,405 Sec#210/212 |
| 1Y MDD | -84.13% | KR#2,333/2,405 Sec#209/212 |
| Trading | ||
| Volume | 129,891 shares | KR#537/2,405 Sec#74/212 |
| Trading Value | 1.12B KRW | KR#560/2,405 Sec#89/212 |
| Foreign Own. | 7.01% | KR#638/2,405 Sec#72/212 |
| Per Share | ||
| EPS | -269 KRW | KR—/2,405 Sec—/212 |
| BPS | 1,625 KRW | KR#2,160/2,405 Sec#191/212 |
Company Info
GemVax, established in 1998 for the manufacturing and sale of Coating Resin and filters, was listed on the KOSDAQ market in 2005. In its environmental pollution control division, the company specializes in localizing Chemical Filters for semiconductor and display applications, as well as providing air pollution prevention equipment. The bio division conducts clinical trials for diseases such as Alzheimer's using GV1001, simultaneously focusing on expanding overseas demand and researching next-generation peptide drugs. GemVax is headquartered in Seongnam City, Gyeonggi-do.